Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30285752 | 1.00 | P2RX4 (0.39) | P2RX4ALDH1A1TSHRMAPK1HRH4 | |
| SCHEMBL30285744 | 0.87 | P2RX4 (0.40) | P2RX4ALDH1A1HRH4PIK3C3L3MBTL1 | |
| SCHEMBL26186428 | 0.87 | P2RX4 (0.40) | P2RX4ALDH1A1HRH4PIK3C3L3MBTL1 | |
| SCHEMBL26186421 | 0.85 | L3MBTL1 (0.45) | P2RX4ALDH1A1PIK3C3OPRD1HTT | |
| SCHEMBL30285833 | 0.85 | L3MBTL1 (0.45) | P2RX4ALDH1A1PIK3C3OPRD1HTT | |
| SCHEMBL26186422 | 0.85 | HRH4 (0.39) | P2RX4ALDH1A1HRH4 | |
| SCHEMBL26186420 | 0.85 | P2RX4 (0.40) | P2RX4ALDH1A1TSHRHRH4OPRD1 | |
| SCHEMBL30285863 | 0.85 | P2RX4 (0.40) | P2RX4ALDH1A1TSHRHRH4OPRD1 | |
| SCHEMBL26186703 | 0.83 | P2RX4 (0.39) | P2RX4ALDH1A1TSHRMAPK1HRH4 | |
| SCHEMBL26186397 | 0.82 | TSHR (0.43) | P2RX4ALDH1A1TSHRHRH4OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257351-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-17 | — | — | US | claimed |
| EP-4172146-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | claimed |
| WO-2022002859-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2022-01-06 | — | — | WO | claimed |
| US-20230270729-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | US | disclosed |
| US-20230270729-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | US | disclosed |
| US-20230257351-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-17 | — | — | US | disclosed |
| US-20230257351-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-17 | — | — | US | disclosed |
| US-20230257351-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-17 | — | — | US | disclosed |
| EP-4172146-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | disclosed |
| CN-115996911-A | Substituted N-phenylacetamides having P2X4 receptor antagonistic activity | 拜耳公司 | 2023-04-21 | — | — | CN | disclosed |
| WO-2022002859-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2022-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257351-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | P2RX2, P2RX5, P2RX3 | P2RX4 4/4885ALDH1A1 882/4885TSHR 1571/4885 |
| US-20230270729-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS | P2RX2, P2RX4, P2RX5 | P2RX4 2/4885ALDH1A1 2885/4885TSHR 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.